Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.36 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 3/20 | 0.35 |
| ▸ | PAICS | P22234 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317792 | 1.00 | ROCK2 (0.37) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL16985335 | 1.00 | ROCK2 (0.37) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 | |
| Hydrochloric Acid SCHEMBL20476166 | 0.99 | CYP1A2 (0.38) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 | |
| Hydrochloric Acid SCHEMBL9951956 | 0.99 | CYP1A2 (0.38) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 | |
| Hydrochloric Acid SCHEMBL30475612 | 0.99 | CYP1A2 (0.38) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL15709846 | 0.91 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP3A5CYP3A7CYP2C19 | |
| Hydrochloric Acid SCHEMBL22518572 | 0.90 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP3A5CYP3A7CYP2C19 | |
| SCHEMBL21639876 | 0.88 | F2 (0.38) | CYP2C19F2PLAUELANEL3MBTL1 | |
| Tert-Butyl Formate SCHEMBL28104950 | 0.87 | KHK (0.35) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 | |
| Tert-Butyl Formate SCHEMBL28104952 | 0.87 | KHK (0.35) | ROCK2ROCK1CYP1A2CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| CN-105940004-A | Compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2016-09-14 | — | — | CN | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | ROCK2 734/4885ROCK1 906/4885CYP1A2 4774/4885 |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | LRRK2, PARK7, WEE1 | ROCK2 775/4885ROCK1 229/4885CYP1A2 4700/4885 |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | LRRK2, PARK7, PAK3 | ROCK2 2142/4885ROCK1 988/4885CYP1A2 3974/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | ROCK2 943/4885ROCK1 1217/4885CYP1A2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.